It is recommended that everyone living with HIV be on HIV treatment, and as soon as possible after diagnosis.
In this guide, HIV drugs are grouped into eight categories —plus, additional categories for select non-HIV drugs and PrEP
This issue of Positively Aware magazine is our 25th Annual HIV Drug Guide, and it’s been quite a ride.
A look at drugs in development for HIV treatment and prevention
Pregnancy and dolutegravir; AIDS Quilt finds a new home; survey on women living with HIV; and more
FDA approves Descovy for PrEP; Delstrigo and Pifeltro approved for switch treatment; Bictegravir, dolutegravir and Tybost for children; and more.
Based on new data, the World Health Organization (WHO) recommended dolutegravir as a preferred HIV drug for all populations living with HIV, including pregnant women and those wanting to conceive.
And other conference highlights including new long-acting drug GS-6207; PrEP on demand; HIV treatment = prevention.
Building blocks for a healthy life, with insights from a nurse educator
Biktarvy and antacids. Descovy FDA hearing. Updated guidelines for transgender individuals. Biktarvy and kids. PrEP4Love. Michael Johnson freed.
Monthly injectable HIV med on the way; HIV pharma sued over pricing practices; Australian PrEP advocate talks about his new HIV status; tenofovir class action lawsuits
New two-drug regimen gets FDA approval. Transgender filmmaker debuts new documentary. Project Inform closes. First kidney transplant from donor living with HIV.
Mixed emotions for a long-term survivor. Peer education in prison. Loving the HIV drug guides and charts.
The experience is your own, but you’re not alone in the room